ASHCROFT PHARMACY
MOUNJARO 2.5MG
Medication features Mounjaro is clinically proven weight loss aid prescribed to help with weight loss when others efforts have been ineffective. It works by acting on hormones responsible for blood sugar and appetite control. This reduces hunger and helps improve blood sugar levels. The once-weekly self-administering pen in user-friendly. This is supplied with enough needles for treatment
£105.00
£150.00
MOUNJARO 5MG
Mounjaro 5mg is one of the lower starting doses of tirzepatide, a once-weekly injectable medication primarily used for: • Type 2 diabetes management • Chronic weight management • Weight loss support: Even the 5mg dose can produce early weight loss in some patients.
£110.00
£160.00
MOUNJARO 7.5MG
Mounjaro 7.5mg is a moderate dose of tirzepatide, used after a patient tolerates lower doses (usually starting at 2.5mg → 5mg). It’s part of a stepped dosing schedule for improving blood sugar control and promoting weight loss. ⸻ 🔹 What to Know About Mounjaro 7.5mg • Frequency: Injected once weekly (same day each week) • Route: Subcutaneous (belly, thigh, or upper arm) • Progression: Typically prescribed after 4+ weeks on 5mg if well tolerated
£129.00
£180.00
MOUNJARO 10MG
Mounjaro 10mg is an advanced mid-to-high dose of tirzepatide, a weekly injectable medication approved for: • Type 2 diabetes management (under Mounjaro) • Chronic weight loss/obesity treatment It’s commonly used after patients build up from lower doses like 2.5mg, 5mg, and 7.5mg. ⸻ 🔹 Key Facts About Mounjaro 10mg • Dosage: Inject once weekly (same day/time each week) • Form: Prefilled auto-injector pen • Pack: Comes in a box of 4 pens (1 month supply)
£149.00
£200.00
MOUNJARO 12.5MG
Mounjaro 12.5mg is a higher dose of tirzepatide, typically used for people who have: • Progressed through lower doses (2.5 → 5 → 7.5 → 10mg) • Tolerated the medication well • Need stronger weight loss or blood sugar control It’s part of the standard step-up dosing schedule designed to reduce side effects while improving long-term effectiveness. 🔹 Quick Facts: Mounjaro 12.5mg Feature Info .🧴 Form Prefilled single-use auto-injector pen .📦 Box Contains 4 pens (1-month supply) .⏱️ Dosing Frequency Once weekly, same day/time each week .💉 Route Subcutaneous (thigh, abdomen, or arm)
£159.00
£210.00
MOUNJARO 15MG
Mounjaro 15mg is the highest approved dose of tirzepatide, used for: • Advanced type 2 diabetes treatment • Significant weight loss goals under medical supervision (also approved as Zepbound for weight loss) It’s typically reached after patients have safely progressed through lower doses like 2.5 → 5 → 7.5 → 10 → 12.5mg. 🔹 Key Details: Mounjaro 15mg Feature Description .🧴 Form Auto-injector pen (prefilled) .📦 Pack 4 pens per box (1 per week) .⏱️ Frequency Once weekly, same day/time .💉 Injection Site Belly, thigh, or upper arm
£179.00
£230.00
CAGRILINITIDE 5MG
Precision Weight Management. Unmatched Value for Researchers. 🔬 Product Overview Cagrilintide is a cutting-edge long-acting amylin analogue developed by Novo Nordisk This dual amylin and calcitonin receptor agonist offers a novel mechanism of action for weight management, providing researchers with a potent tool for metabolic health studies. 🚀 Key Benefits *Dual Receptor Activation: Simultaneously targets amylin and calcitonin receptors to regulate appetite, enhance satiety, and modulate glucose metabolism. *Clinically Proven Efficacy: Clinical studies have demonstrated that Cagrilintide leads to clinically significant, dose-dependent weight loss, with greater reductions observed at higher doses. *Enhanced Metabolic Health: Treatment with Cagrilintide has been associated with significant reductions in body weight and improved metabolic parameters. *Cost-Effective Research Tool: The 5mg vial offers a more affordable option for extended research protocols, reducing the cost per milligram compared to higher doss. 🧪 Composition *Active Ingredient: Cagrilintide *Concentration: 5mg per vial. *Form: Lyophilized peptide powder. 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period. 🛒 Order your 5mg Cagrilintide today for £200.00 (with free injection pen)
£140.00
£200.00
CAGRILINITIDE 10MG
CAGRILINITIDE is a cutting-edge long-acting amylin analogue developed by Novo Norodisk. This dual amylin and calcitonin receptor agonist offers a novel mechanism of action for weight management, providing researchers with a potent tool for a metabolic health studies.
£200.00
£300.00
RETATRUTIDE 30MG
Retatrutide 30mg is a next-generation injectable weight loss and diabetes drug currently in clinical development by Eli Lilly. It’s not yet approved by the FDA as of 2025, but it’s widely considered the most powerful obesity drug ever tested in clinical trials — even stronger than Mounjaro (tirzepatide). ⸻ 🔬 What Is Retatrutide? • Type: Triple hormone receptor agonist → Acts on GLP-1, GIP, and glucagon receptors • Dose: 30mg is the highest dose tested in clinical trials • Frequency: Once-weekly injection • Brand Name: Not yet announced (in development) ⸻ ⚙️ How Retatrutide Works It targets three metabolic pathways to: 1. Suppress appetite (like GLP-1s) 2. Enhance energy expenditure (via glucagon receptor) 3. Improve blood sugar control (via GIP and GLP-1) ⸻ 💥 Weight Loss Results (Clinical Trial Data) In a major Phase 2 trial, retatrutide 30mg led to: ✅ Average weight loss: 24.2% in 48 weeks ✅ Over 58 lbs lost (on average) for people starting around 240 lbs ✅ Results that exceeded tirzepatide (Mounjaro/Zepbound) These outcomes are unmatched by any currently approved medication.
£230.00
RETATRUTIDE 10MG Pen
Triple-Pathway Fat Loss. Maximum Metabolic Power. 🔬 Product Overview Retatrutide is a cutting-edge triple hormone receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. This multifaceted approach offers unparalleled potential in weight loss and metabolic health research. 🚀 Key Benefits Triple Hormone Activation: Engages GLP-1, GIP, and glucagon receptors to synergistically enhance weight loss and metabolic regulation. Superior Weight Reduction: In a 48-week phase 2 study, participants experienced up to 24.2% body weight loss with 12 mg dosing, surpassing results from other treatments like Ozempic and Mounjaro citeturn0search0. Enhanced Metabolic Health: Demonstrated improvements in liver fat content and cardiometabolic markers, indicating broader health benefits citeturn0search11. Reduced Dosing Frequency: Due to its potency, one vial will last for 5+weeks, depending on the research protocol. 🧪 Composition Active Ingredient: Retatrutide Concentration: 10mg per vial Form: Lyophilized peptide powder 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period. 🧠 Why Retatrutide Stands Out More Effective: Achieves greater weight loss in a shorter time frame compared to GLP-1 mono-agonists and dual agonists. Comprehensive Approach: Addresses multiple pathways involved in weight regulation and metabolic health. Research-Backed: Supported by robust clinical data demonstrating its efficacy and potential benefits citeturn0search0. 🔥 Pioneering the Future of Weight Loss Research Retatrutide represents a significant advancement in the field of metabolic research. Its unique triple-action mechanism offers a promising avenue for studies focused on obesity, type 2 diabetes, and related metabolic disorders.
£105.00
RETATRUTIDE 20MG Pen
Active Ingredient: Retatrutide Concentration: 20mg per vial Form: Lyophilized peptide powder 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period.
£199.00
SEMAGLUTIDE 10MG
Semaglutide is a GLP-1 receptor agonist available for research purposes only. It has shown significant potential in clinical studies for appetite suppression, weight loss, and blood sugar regulation. Available in 10mg, 20mg, and 30mg, this flexible dosing makes it an excellent option for researchers studying metabolic and weight loss treatments. Key Benefits: For research purposes only Effective for appetite suppression and metabolic regulation Flexible dosing options (10mg, 20mg, 30mg) Affordable and accessible for scientific studies (with free injection pen)
£139.99
£170.00
TIRZEPATIDE 10MG
Tirzepatide is a dual-action GLP-1 and GIP receptor agonist available for research purposes only. Its powerful combination of receptor activity has shown promising results in research for weight loss and metabolic health. Available in 10mg, 20mg, and 30mg, Tirzepatide offers an innovative approach for researchers exploring advanced metabolic and weight loss solutions. Key Benefits: For research purposes only Dual-action mechanism (GLP-1 and GIP) for enhanced metabolic effects Available in 10mg, 20mg, and 30mg doses for flexible research Ideal for advanced weight loss and metabolic health studies
£124.99
£150.00
TIRZEPATIDE 20MG
🧪 Key difference: • The 20mg/mL vial is more concentrated, so you draw less liquid to get the same dose. • This matters when injecting with insulin syringes (measured in units).
£174.99
£210.00
TIRZEPATIDE 30MG
30MG Tirzepatide is double dosage, double strength = double results. Higher dose means faster weight loss but not guaranteed benefits.
£269.99
MOUNJARO 10MG
Mounjaro 10mg is an advanced mid-to-high dose of tirzepatide, a weekly injectable medication approved for: • Type 2 diabetes management (under Mounjaro) • Chronic weight loss/obesity treatment It’s commonly used after patients build up from lower doses like 2.5mg, 5mg, and 7.5mg. ⸻ 🔹 Key Facts About Mounjaro 10mg • Dosage: Inject once weekly (same day/time each week) • Form: Prefilled auto-injector pen • Pack: Comes in a box of 4 pens (1 month supply)
£149.00
£200.00
MOUNJARO 12.5MG
Mounjaro 12.5mg is a higher dose of tirzepatide, typically used for people who have: • Progressed through lower doses (2.5 → 5 → 7.5 → 10mg) • Tolerated the medication well • Need stronger weight loss or blood sugar control It’s part of the standard step-up dosing schedule designed to reduce side effects while improving long-term effectiveness. 🔹 Quick Facts: Mounjaro 12.5mg Feature Info .🧴 Form Prefilled single-use auto-injector pen .📦 Box Contains 4 pens (1-month supply) .⏱️ Dosing Frequency Once weekly, same day/time each week .💉 Route Subcutaneous (thigh, abdomen, or arm)
£159.00
£210.00
MOUNJARO 2.5MG
Medication features Mounjaro is clinically proven weight loss aid prescribed to help with weight loss when others efforts have been ineffective. It works by acting on hormones responsible for blood sugar and appetite control. This reduces hunger and helps improve blood sugar levels. The once-weekly self-administering pen in user-friendly. This is supplied with enough needles for treatment
£105.00
£150.00
MOUNJARO 7.5MG
Mounjaro 7.5mg is a moderate dose of tirzepatide, used after a patient tolerates lower doses (usually starting at 2.5mg → 5mg). It’s part of a stepped dosing schedule for improving blood sugar control and promoting weight loss. ⸻ 🔹 What to Know About Mounjaro 7.5mg • Frequency: Injected once weekly (same day each week) • Route: Subcutaneous (belly, thigh, or upper arm) • Progression: Typically prescribed after 4+ weeks on 5mg if well tolerated
£129.00
£180.00
MOUNJARO 5MG
Mounjaro 5mg is one of the lower starting doses of tirzepatide, a once-weekly injectable medication primarily used for: • Type 2 diabetes management • Chronic weight management • Weight loss support: Even the 5mg dose can produce early weight loss in some patients.
£110.00
£160.00
MOUNJARO 15MG
Mounjaro 15mg is the highest approved dose of tirzepatide, used for: • Advanced type 2 diabetes treatment • Significant weight loss goals under medical supervision (also approved as Zepbound for weight loss) It’s typically reached after patients have safely progressed through lower doses like 2.5 → 5 → 7.5 → 10 → 12.5mg. 🔹 Key Details: Mounjaro 15mg Feature Description .🧴 Form Auto-injector pen (prefilled) .📦 Pack 4 pens per box (1 per week) .⏱️ Frequency Once weekly, same day/time .💉 Injection Site Belly, thigh, or upper arm
£179.00
£230.00
RETATRUTIDE 10MG Pen
Triple-Pathway Fat Loss. Maximum Metabolic Power. 🔬 Product Overview Retatrutide is a cutting-edge triple hormone receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. This multifaceted approach offers unparalleled potential in weight loss and metabolic health research. 🚀 Key Benefits Triple Hormone Activation: Engages GLP-1, GIP, and glucagon receptors to synergistically enhance weight loss and metabolic regulation. Superior Weight Reduction: In a 48-week phase 2 study, participants experienced up to 24.2% body weight loss with 12 mg dosing, surpassing results from other treatments like Ozempic and Mounjaro citeturn0search0. Enhanced Metabolic Health: Demonstrated improvements in liver fat content and cardiometabolic markers, indicating broader health benefits citeturn0search11. Reduced Dosing Frequency: Due to its potency, one vial will last for 5+weeks, depending on the research protocol. 🧪 Composition Active Ingredient: Retatrutide Concentration: 10mg per vial Form: Lyophilized peptide powder 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period. 🧠 Why Retatrutide Stands Out More Effective: Achieves greater weight loss in a shorter time frame compared to GLP-1 mono-agonists and dual agonists. Comprehensive Approach: Addresses multiple pathways involved in weight regulation and metabolic health. Research-Backed: Supported by robust clinical data demonstrating its efficacy and potential benefits citeturn0search0. 🔥 Pioneering the Future of Weight Loss Research Retatrutide represents a significant advancement in the field of metabolic research. Its unique triple-action mechanism offers a promising avenue for studies focused on obesity, type 2 diabetes, and related metabolic disorders.
£105.00
RETATRUTIDE 20MG Pen
Active Ingredient: Retatrutide Concentration: 20mg per vial Form: Lyophilized peptide powder 📦 Usage & Storage Intended Use: For research purposes only Storage: Store lyophilized powder in a cool, dry place. After reconstitution, refrigerate at 2–8°C and use within the designated study period.
£199.00
RETATRUTIDE 30MG
Retatrutide 30mg is a next-generation injectable weight loss and diabetes drug currently in clinical development by Eli Lilly. It’s not yet approved by the FDA as of 2025, but it’s widely considered the most powerful obesity drug ever tested in clinical trials — even stronger than Mounjaro (tirzepatide). ⸻ 🔬 What Is Retatrutide? • Type: Triple hormone receptor agonist → Acts on GLP-1, GIP, and glucagon receptors • Dose: 30mg is the highest dose tested in clinical trials • Frequency: Once-weekly injection • Brand Name: Not yet announced (in development) ⸻ ⚙️ How Retatrutide Works It targets three metabolic pathways to: 1. Suppress appetite (like GLP-1s) 2. Enhance energy expenditure (via glucagon receptor) 3. Improve blood sugar control (via GIP and GLP-1) ⸻ 💥 Weight Loss Results (Clinical Trial Data) In a major Phase 2 trial, retatrutide 30mg led to: ✅ Average weight loss: 24.2% in 48 weeks ✅ Over 58 lbs lost (on average) for people starting around 240 lbs ✅ Results that exceeded tirzepatide (Mounjaro/Zepbound) These outcomes are unmatched by any currently approved medication.
£230.00
OZEMPIC 0.25MG
Ozempic 0.25 mg is the starting dose of semaglutide, primarily used to treat type 2 diabetes and often used off-label to assist with weight loss. However, 0.25 mg is not a therapeutic dose for blood sugar control—it’s mainly used to help the body adjust to the medication and reduce side effects like nausea. ⸻ 🔹 Ozempic 0.25 mg – At a Glance • Generic name: Semaglutide • Class: GLP-1 receptor agonist • Brand name: Ozempic • Typical use: • Initiation of therapy for type 2 diabetes • Often the first 4 weeks of therapy before increasing the dose ⸻ 💉 Dosing Schedule • Start with 0.25 mg once weekly for 4 weeks • Then increase to 0.5 mg once weekly if tolerated • If needed, your doctor may increase it further to 1 mg or even 2 mg ⸻ 📌 Important Notes • Not effective for glucose control on its own: 0.25 mg is too low to control blood sugar but helps minimize side effects as your body adjusts. • Same injection day each week (doesn’t matter if it’s with food) • Inject subcutaneously in the abdomen, thigh, or upper arm
£104.99
£130.00
OZEMPIC 0.5MG
Ozempic 0.5 mg is the first therapeutic dose of semaglutide (a GLP-1 receptor agonist) used for: • Type 2 diabetes management • Weight loss (off-label use) This is typically the dose patients move to after completing 4 weeks on the starter dose of 0.25 mg, once the body has adjusted to the medication. ⸻ 🔹 Ozempic 0.5 mg – Quick Facts • Generic name: Semaglutide • Form: Injectable pen (subcutaneous) • Frequency: Once weekly • Dose schedule: • Week 1–4: 0.25 mg • Week 5 onward: 0.5 mg • May increase to 1 mg or 2 mg if needed
£109.99
£150.00
OZEMPIC 1MG
Ozempic 1 mg refers to a specific dosage of semaglutide, a medication used primarily to help manage blood sugar levels in adults with type 2 diabetes. It also has benefits for weight loss and cardiovascular risk reduction. Here’s a quick overview: ⸻ Ozempic (Semaglutide) 1 mg – Key Information • Drug class: GLP-1 receptor agonist • Indication: • Type 2 diabetes (to improve glycemic control) • Sometimes prescribed off-label for weight loss (though Wegovy, another brand of semaglutide, is FDA-approved for weight loss) • Usual Dosage Schedule: • Injected once weekly • Usually started at 0.25 mg for 4 weeks • Increased gradually to 0.5 mg, then 1 mg if needed • A higher 2 mg dose is also available for patients needing further control • Administration: • Subcutaneous injection (abdomen, thigh, or upper arm) • Same day/time each week (with or without meals) • Common Side Effects: • Nausea, vomiting, diarrhea, constipation • Decreased appetite • Injection site reactions • Serious Risks: • Risk of thyroid C-cell tumors (boxed warning) • Pancreatitis, kidney problems, or gallbladder issues (rare but serious)
£129.99
£180.00
WEGOVY 0.25MG
Wegovy 0.25 mg is the starting dose of semaglutide for chronic weight management in adults who are overweight or obese. It’s not a therapeutic dose, but rather an introductory dose to help your body adjust and minimize side effects like nausea. ⸻ 🔹 Wegovy 0.25 mg – Overview • Active ingredient: Semaglutide (same as Ozempic) • Brand: Wegovy • FDA-approved use: • Chronic weight management in adults with: • BMI ≥30 (obesity), or • BMI ≥27 (overweight) with at least one weight-related condition (e.g., high blood pressure, type 2 diabetes, high cholesterol)
£104.99
£130.00
WEGOVY 0.5MG
Wegovy 0.5 mg is the second step in the titration schedule for weight loss treatment using semaglutide. Like 0.25 mg, it is not a full therapeutic dose, but a transitional one designed to gradually prepare your body for the target dose of 2.4 mg weekly. ⸻ 🔹 Wegovy 0.5 mg – Quick Overview • Active ingredient: Semaglutide • Brand: Wegovy (not Ozempic — though both use semaglutide) • Primary use: Chronic weight management in adults who are: • Obese (BMI ≥30), or • Overweight (BMI ≥27) with weight-related conditions
£109.99
£160.00
WEGOVY 1MG
Wegovy 1 mg is the third step in the titration schedule for weight management with semaglutide. At this dose, most people begin to see more noticeable weight loss, though it’s still not the final therapeutic dose. ⸻ 🔹 Wegovy 1 mg – At a Glance • Active Ingredient: Semaglutide • Brand: Wegovy • Dose: 1 mg injected once weekly • Use: • Chronic weight management for adults with: • BMI ≥30, or • BMI ≥27 with at least one weight-related condition (e.g., high blood pressure, type 2 diabetes, high cholesterol)
£129.99
£180.00
ZEPBOUND 2.5MG
💉 What is the 2.5 mg dose? • Zepbound (tirzepatide) is a once‑weekly injectable medication approved for chronic weight management and moderate‑to‑severe obstructive sleep apnea (OSA) in adults with obesity . • The 2.5 mg dose is the starter dose, intended to begin therapy and slowly acclimate your body . ⏳ How is the dosing schedule structured? After 4 weeks at 2.5 mg, the dose increases to 5 mg. From there, your provider may raise it in 2.5 mg increments every 4 weeks—based on your response and side effects—until maintenance or maximum dosing is reached . ⸻ 🛑 Important notes on the 2.5 mg dose • This dose is not intended for long-term use—it’s only for the first month of treatment (). • Staying on 2.5 mg beyond 4 weeks means you’re not in the maintenance phase—which could blunt the medication’s full effectiveness (). ⸻ ⚠️ Why start at just 2.5 mg? • It helps minimize common side effects like nausea, vomiting, or diarrhea. • According to the prescribing guide, a gradual dose escalation lowers risk of GI discomfort
£229.99
£279.99
ZEPBOUND 5MG
📈 What is the 5 mg dose? • Zepbound (tirzepatide) is a weekly injectable for chronic weight management in adults with obesity or overweight plus comorbidities—also approved for moderate-to-severe obstructive sleep apnea (OSA) . • After starting at 2.5 mg weekly for four weeks, you advance to 5 mg weekly, which begins the maintenance phase for most users seeking weight loss . 🌟 Role of 5 mg in therapy • Transition dose: 5 mg marks the shift from initiation to potential maintenance. • Maintenance efficacy: • Clinical data show ~15% average weight loss at 5 mg over 72 weeks (). • For many, 5 mg sustains satisfactory results; for others, increases up to 15 mg may be considered if needed . ⸻ 💊 How dosing progresses 1. Weeks 1–4: 2.5 mg to initiate therapy. 2. Week 5 onward: Move to 5 mg weekly. 3. Every 4+ weeks thereafter: Option to bump up by 2.5 mg to 7.5, 10, 12.5, up to 15 mg, guided by tolerability and goals
£249.99
ZEPBOUND 7.5 MG
🧭 Where 7.5 mg Fits in the Dosing Path • After starting at 2.5 mg for 4 weeks and moving to 5 mg maintenance, 7.5 mg is the next logical step if weight loss plateaus or goals aren’t met. • It sits mid-way in the escalation ladder: 2.5 → 5 → 7.5 → 10 → up to 15 mg. ⸻ 💪 Efficacy at 7.5 mg • Clinical trials show a dose-dependent effect: higher dose yields greater weight loss—approximately 15% at 5 mg, 20%+ at 15 mg after 72 weeks . • Meta-analyses confirm significant superiority over placebo and even semaglutide at higher doses (). • While specific 7.5 mg data isn’t separated in sources, outcomes from 10 mg and 15 mg indicate that 7.5 mg likely yields weight loss between 5 mg and 10 mg results—a meaningful step up. ⸻ ⚠️ Side Effects & Tolerability • GI issues (nausea, diarrhea, vomiting, constipation, abdominal pain) typically increase with higher doses . • A side-effect guide shows similar issues persisted at 7.5 mg . Reddit user experiences highlight real-world reactions: “The nausea on 7.5 is terrifying…I vomited and I felt so much better”  “I’ve been terribly sick after 5.0 then 7.5…nausea and diarrhea is awful”  However, some find 7.5 manageable: “Stayed on it an extended period…Fav dose. Felt the best… energized…”
£259.99
